Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.
Type:
Application
Filed:
December 27, 2012
Publication date:
June 20, 2013
Applicants:
OXFORD BIOTHERAPEUTICS LTD, MEDAREX, INC.
Abstract: The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
Type:
Grant
Filed:
December 28, 2007
Date of Patent:
June 11, 2013
Assignee:
Medarex, Inc.
Inventors:
Bilal Sufi, Vincent Guerlavais, Liang Chen, Sanjeev Gangwar, Qian Zhang, David B. Passmore
Abstract: A purpose of the present invention is to provide a method capable of more effectively prescribing an anti-human PD-1 antibody for anti-cancer therapy, a method for estimating or optimizing therapeutic efficacy thereof, and further an efficacy marker that can be used in methods thereof. The present invention enables selection of the cancer patient in whom the therapeutic efficacy of the anti-human PD-1 antibody can be expected in future, by measuring the change which is more than a certain level of several kinds of efficacy markers in blood, after administering the initial dose or doses of the anti-human PD-1 antibody compared to that prior to administering the initial dose, and provides a new prescription of the anti-human PD-1 antibody for anti-cancer therapy.
Type:
Grant
Filed:
July 3, 2009
Date of Patent:
June 11, 2013
Assignees:
Ono Pharmaceutical Co., Ltd., Medarex, Inc.
Abstract: The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMA+ cells, such as tumor cells, are also provided.
Type:
Grant
Filed:
October 13, 2010
Date of Patent:
June 11, 2013
Assignee:
Medarex, Inc.
Inventors:
Josephine M. Cardarelli, David B. Passmore, Jenny Albanese, Lei Zhu
Abstract: The present invention provides isolated human monoclonal antibodies that bind to IFNAR-1 and that are capable of inhibiting the biological activity of Type I interferons. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting Type I interferon-mediated disorders using the antibodies of the invention, including methods for treating autoimmune disorders, transplant rejection or Graft Versus Host Disease using the antibodies of the invention.
Type:
Grant
Filed:
February 12, 2010
Date of Patent:
June 11, 2013
Assignee:
Medarex, Inc.
Inventors:
Josephine M. Cardarelli, Alison Witte, Mohan Srinivasan
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.
Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Type:
Grant
Filed:
January 27, 2012
Date of Patent:
June 4, 2013
Assignees:
Amgen Inc., Medarex, Inc.
Inventors:
William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
Abstract: The present disclosure provides isolated monoclonal antibodies that specifically bind to CXCR4 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CXCR4, as well as methods for treating various cancers, inflammatory disorders and HIV infection using an anti-CXCR4 antibody of this disclosure.
Type:
Grant
Filed:
October 1, 2007
Date of Patent:
May 28, 2013
Assignee:
Medarex, Inc.
Inventors:
Michelle Kuhne, Peter Brams, Dawn M. Tanamachi, Alan J. Korman, Josephine M. Cardarelli
Abstract: The present invention provides isolated monoclonal antibodies, particularly human monoclonal antibodies, that specifically bind to PD-1 with high affinity. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for detecting PD-1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-1 antibodies. The present invention further provides methods for using a combination immunotherapy, such as the combination of anti-CTLA-4 and anti-PD-1 antibodies, to treat hyperproliferative disease, such as cancer. The invention also provides methods for altering adverse events related to treatment with such antibodies individually.
Type:
Application
Filed:
August 15, 2011
Publication date:
May 23, 2013
Applicants:
Ono Pharmaceutical Co., LTD., Medarex, Inc.
Inventors:
Alan J. Korman, Mohan Srinivasan, Changyu Wang, Mark J. Sellby, Bing Chen, Josephine M. Cardarelli, Haichun Huang
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, more particularly engineered antibodies resulting in increased binding to Fc receptors and/or increased potency for ADCC or immunoconjugates, which specifically bind to CADM1 with high affinity. Nucleic acid molecules encoding CADM1 antibodies, expression vectors, host cells and methods for expressing the CADM1 antibodies are also provided. Bispecific molecules and pharmaceutical compositions comprising the CADM1 antibodies are also provided. Methods for detecting CADM1, as well as methods for treating various cancers, including lung cancer and pancreatic cancer, are disclosed.
Abstract: The present invention provides methods and compositions for treatment, screening, diagnosis, prognosis and therapy of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer, for monitoring the effectiveness of breast cancer, colorectal cancer, esophageal cancer, gastric cancer, prostate cancer and uterine cancer treatment, and for drug development.
Type:
Grant
Filed:
February 7, 2010
Date of Patent:
April 16, 2013
Assignees:
Oxford BioTherapeutics Ltd., Medarex, Inc.
Inventors:
Christian Rohlff, Jonathan Alexander Terrett
Abstract: Isolated human monoclonal antibodies which bind to Anthrax protective antigen are disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
Type:
Grant
Filed:
October 7, 2008
Date of Patent:
March 26, 2013
Assignee:
Medarex, Inc.
Inventors:
Tibor Keler, Israel Lowy, Laura A. Vitale, Diann Blanset, Mohan Srinivasan
Abstract: The present disclosure provides drug-ligand conjugates that are potent cytotoxins, wherein the drug is linked to the ligand through either a peptidyl, hydrazine, or disulfide linker. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
Type:
Grant
Filed:
November 2, 2009
Date of Patent:
March 19, 2013
Assignee:
Medarex, Inc.
Inventors:
Sharon E. Boyd, Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Kilian Horgan, Zhi-Hong Li, Bilal Sufi
Abstract: Antiproliferative compounds having a structure represented by formula (II), where n, R1, R2, R3, R4, and R5 are as defined herein, can be used to treat tumors, optionally when conjugated to a ligand such as an antibody:
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.
Type:
Grant
Filed:
April 21, 2011
Date of Patent:
February 26, 2013
Assignee:
Medarex, Inc.
Inventors:
Alan J. Korman, Mark J. Selby, Changyu Wang, Mohan Srinivasan, David B. Passmore, Haichun Huang, Haibin Chen
Abstract: The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.
Type:
Grant
Filed:
December 8, 2006
Date of Patent:
February 26, 2013
Assignee:
Medarex, Inc.
Inventors:
Cynthia A. Vistica, Eric H. Holmes, Peter Brams, Alison Witte, Josephine M. Cardarelli
Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
Type:
Grant
Filed:
May 18, 2010
Date of Patent:
February 5, 2013
Assignees:
Amgen, Inc., Medarex, Inc.
Inventors:
William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
Abstract: The present invention relates to a method of enhancing the anti-tumor response in a mammal. More particularly, the invention is concerned with combinations comprising a cytokine-secreting cell and an anti-PD-1 antibody, and methods of administering the combination for enhanced immune response to tumor cells in a patient with a cancer.
Type:
Application
Filed:
September 14, 2012
Publication date:
January 24, 2013
Applicants:
Medarex, Inc., BioSante Pharmaceuticals, Inc.